Clinical trials: Alzheimer's Disease Dementia
Dementia, Dementia Alzheimer Type
Dynamic Light Scattering Ocular Measurement in the Detection of Dementia
This is a human clinical study making a noninvasive measurement from a patient's eye to determine whether there is a quantitative difference in measurements between patients with and without the diagnosis of dementia.
- Trial name
- DLS (NCT06613971)
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- MD Stem Cells
Alzheimer Disease
Safety and Efficacy of TRx0237 in Subjects With Alzheimer's Disease Followed by Open-Label Treatment
The purpose of this study is to determine the safety and efficacy of TRx0237 16 mg/day and 8 mg/day in the treatment of subjects with Alzheimer's Disease compared to placebo.
- Trial name
- NCT03446001
- Testing
- TRx0237 16 mg/day, Control, TRx0237 8 mg/day
- Where
- 103 sites in United States, Belgium and 6 more
- Volunteers
- 598 people
- Sponsor
- TauRx Therapeutics Ltd
Healthy Volunteers, Moderate to Severe Alzheimer Patients
A Randomized SAD and MAD Study Evaluating the Safety and Tolerability of RPh201 in Healthy Subjects and in Adults With Alzheimer's Disease
This is a dual-centre, Phase I/IIa study, in healthy subjects and subjects with AD to investigate the safety, tolerability, cognitive, and behavioural effects of RPh201.
- Trial name
- NCT01513967
- Testing
- RPh201, botanical drug product
- Where
- 2 sites in Canada
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Regenera Pharma Ltd
Alzheimer Disease, Alzheimer' Disease
A Phase 2 Study to Evaluate the Safety and Efficacy of BEY2153 in Patients with Early Alzheimer's Disease
The purpose of this study is to investigate the safety and efficacy of BEY2153 in patients with early Alzheimer's Disease. Subjects who meet the inclusion and exclusion criteria will be randomized 1:1:1 to one of three treatment…
- Trial name
- NCT06885567
- Testing
- BEY2153
- Where
- 3 sites in South Korea
- Volunteers
- 90 people
- Sponsor
- BeyondBio Inc.
Alzheimers Disease
A Post Authorization Registry Study of Participants Treated With LEQEMBI
To describe the incidence and severity of known adverse events, including amyloid-related imaging abnormalities-edema (ARIA-E), ARIA microhemorrhage and hemosiderin deposit (ARIA-H), and intracerebral hemorrhage greater than 1 cm…
- Trial name
- NCT07762092
- Testing
- No Intervention
- Where
- 17 sites in Canada
- Volunteers
- 400 people
- Sponsor
- Eisai Limited
Alzheimer's Disease
Safety and Tolerability of Dimebon in Patients on Memantine, and Memantine Plus Donepezil
The purpose of this study is to evaluate the safety and tolerability of dimebon given to Alzheimer's disease patients currently on a stable dose and regimen of memantine or memantine plus donepezil.
- Trial name
- NCT00829816
- Testing
- Dimebon
- Where
- 4 sites in United States
- Volunteers
- 46 people
- Sponsor
- Medivation, Inc.
Alzheimer Disease, MCI
Detecting an MCI and Amyloid Digital Neuro Signature(DNS) Using Altoida's Multimodal Digital Biomarkers.
The purpose of this study is to establish multiple points of clinical validity for the Altoida digital biomarker assessment in individuals with a clinical diagnosis of cognitively normal (CN) and Mild Cognitive Impairment (MCI).
- Trial name
- NCT06223438
- Where
- United States
- Volunteers
- 614 people, healthy volunteers welcome
- Sponsor
- Altoida
Alzheimer's Disease
Memantine - Communication Study
The study objective is to evaluate the effects of memantine treatment on communication abilities and other cognitive abilities in moderate to severe DAT patients.
- Trial name
- NCT00624026
- Testing
- Memantine-HCl
- Where
- Germany
- Volunteers
- 107 people
- Sponsor
- Merz Pharmaceuticals GmbH
Alzheimer's Disease
12-Month Open-Label Extension Study of Intepirdine (RVT-101) in Subjects With Alzheimer's Disease: MINDSET Extension
This 12-month open-label study will provide further information regarding the long-term safety and tolerability of intepirdine (RVT-101) for subjects with Alzheimer's disease who have completed the double-blind…
- Trial name
- NCT02586909
- Testing
- RVT-101 35 mg tablets
- Where
- 169 sites in United States, Argentina and 17 more
- Volunteers
- 1,099 people
- Sponsor
- Axovant Sciences Ltd.
Dementia, Alzheimer Disease
Community-based Brain Health Program to Address Dementia Risk
This is a validation study to evaluate the acceptability, feasibility and preliminary efficacy of the Brain Health Program, a multimodal curriculum covering dementia risk factors and evidence-based change interventions.
- Trial name
- C-BBHP (NCT05529706)
- Testing
- Brain Health Program
- Where
- United States
- Volunteers
- 86 people
- Sponsor
- Posit Science Corporation
Parkinson Disease
A Study to Assess the Safety of BMS-984923 Compared to Placebo, in People With Parkinson's
A Phase 1, randomized, double-blind, placebo-controlled study of BMS-984923 administered orally twice daily (BID) for 28 days in participants with Parkinson's disease.
- Trial name
- NCT06309147
- Testing
- BMS-9894923
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Allyx Therapeutics
Alzheimer's Disease
Safety/Tolerability, Immunological and Clinical Activity of a Boost Immunization With AFFITOPE AD02
This is a phase IB follow-up study to assess a boost immunization with AFFITOPE AD02 with regard to safety/tolerability, immunological and clinical activity in Alzheimer patients who have received the vaccine within the clinical…
- Trial name
- NCT01093664
- Testing
- AFFITOPE AD02
- Where
- Austria
- Volunteers
- 20 people
- Sponsor
- Affiris AG
Alzheimer Disease
Follow-up Trial to Assess the Long-term Safety and Tolerability of Talsaclidine in Patients With Mild to Moderate Dementia of the Alzheimer Type
Safety and tolerability. Quality of life (EQ-5D, ACQLI) and health economic impact (health resource utilisation, living and employment status) assessments, will not be performed at the centers in the united kingdom (UK)
- Trial name
- NCT02248116
- Testing
- Talsaclidine
- Volunteers
- 198 people
- Sponsor
- Boehringer Ingelheim
Alzheimer Disease
A Study of JNJ-64042056 in Participants With Preclinical Alzheimer's Disease
The purpose of this study is to assess whether JNJ-64042056 affects the spread and build up of tau (a protein in brain) when compared with placebo, using brain scan (tau PET) to determine results from specific areas of the brain.
- Trial name
- Reτain (NCT06544616)
- Testing
- JNJ-64042056
- Where
- 90 sites in United States, Australia and 7 more
- Volunteers
- 55 people
- Sponsor
- Janssen Pharmaceutica N.V., Belgium
Dementia, Alzheimer Type
A Phase II Study to Assess the Safety, Tolerability and Efficacy of Xanamem™ in Subjects With Mild Dementia Due to AD (XanADu)
This XanADu Phase II study in mild Alzheimer's Disease (AD) is to assess the safety, tolerability and efficacy of Xanamem in subjects with mild dementia due to Alzheimer's Disease.
- Trial name
- XanADu (NCT02727699)
- Testing
- Xanamem™
- Where
- 25 sites in United States, Australia and 1 more
- Volunteers
- 185 people
- Sponsor
- Actinogen Medical
Alzheimer Disease
Analysis of XTR006 PET Imaging in Non-cognitively Impaired Subjects, MCI Due toAD, and Mild to Moderate AD Subjects
This is an investigator-initiated clinical (IIT)study.The main purpose of this study was to evaluate the diagnostic efficacy of XTR006 PET qualitative reading and quantitative analysis in detecting mild cognitive…
- Trial name
- NCT06151808
- Testing
- XTR006
- Where
- China
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Sinotau Pharmaceutical Group
Alzheimer's Disease
AAB-001 (Bapineuzumab) Open-Label, Long-Term Extension Study in Patients With Mild to Moderate Alzheimer's Disease
This is a multicenter, open-label, long-term extension study in male and female patients with mild to moderate Alzheimer's Disease (AD) who must have completed one of the following studies: AAB-001-201 or AAB-001-102.
- Trial name
- NCT00606476
- Testing
- Bapineuzumab (AAB-001)
- Where
- 29 sites in United States
- Volunteers
- 194 people
- Sponsor
- JANSSEN Alzheimer Immunotherapy Research & Development, LLC
Dementia, Alzheimer Disease
A Study of the Effectiveness and Safety of Risperidone in the Treatment of Behavioral Disturbances in Patients With Dementia
The purpose of the study is to compare the effectiveness of an oral formulation of risperidone (an antipsychotic medication) to that of placebo for treating behavioral and psychological signs and symptoms in dementia (BPSSD)…
- Conditions
- Dementia, Alzheimer Disease, Vascular Dementia
- Trial name
- NCT00249158
- Testing
- Risperidone
- Volunteers
- 344 people
- Sponsor
- Janssen-Cilag Pty Ltd
Alzheimer's Disease
Study Evaluating The Safety Of AAB-003 (PF-05236812) In Subjects With Alzheimer's Disease
This is a study to evaluate the safety of multiple doses of AAB-003 (PF-05236812) in patients with mild to moderate Alzheimer's Disease. Patients will receive either AAB-003 (PF-05236812) or placebo.
- Trial name
- NCT01193608
- Testing
- AAB-003 (PF-05236812)
- Where
- 29 sites in United States, South Korea
- Volunteers
- 88 people
- Sponsor
- Pfizer
Alzheimer's Disease
A Study Assessing Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease
This is a randomized double-blind placebo-controlled study comparing different doses of bryostatin for the treatment of moderately severe to severe Alzheimer's disease.
- Trial name
- NCT02431468
- Testing
- Bryostatin 1
- Where
- 29 sites in United States
- Volunteers
- 147 people
- Sponsor
- Neurotrope Bioscience, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.